Download

Full Text

• Jain, A., Zhang, Q., Toh, H.C., Awakening immunity against cancer: a 2017 primer for clinicians. Chin J Cancer, 36, 2017, 67.
• Lyon, A.R., Yousaf, N., Battisti, N.M.L., Moslehi, J., Larkin, J., Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19 (2018), e447–e458.
• Brudno, J.N., Kovkenderfer, J.N., Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127 (2016), 3321–3330.
• Alvi, R.M., Frigault, M.J., Fradeley, M.G., et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol 74 (2019), 3099–3108.
• Liu, D., Zhao, J., Cytokine release syndrome: grading, modeling, and new therapy. J Hematol Oncol, 11, 2018, 121.
• Le, R.Q., Li, L., Yuan, W., et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23 (2018), 943–947.
• Lancellotti, P., Suter, T.M., Lopez-Fernandez, T., et al. Cardio-oncology service: rationale, organization, and implementation. Eur Heart J 40 (2019), 1756–1763.